S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Buy THIS stock before Taiwan is attacked (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
BREAKING: Tiny biotech successfully treats blindness (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
Buy THIS stock before Taiwan is attacked (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Buy THIS stock before Taiwan is attacked (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
BREAKING: Tiny biotech successfully treats blindness (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
Buy THIS stock before Taiwan is attacked (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Buy THIS stock before Taiwan is attacked (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
BREAKING: Tiny biotech successfully treats blindness (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
Buy THIS stock before Taiwan is attacked (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Buy THIS stock before Taiwan is attacked (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
BREAKING: Tiny biotech successfully treats blindness (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
Buy THIS stock before Taiwan is attacked (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
NASDAQ:CNTA

Centessa Pharmaceuticals (CNTA) Stock Forecast, Price & News

$6.47
+0.25 (+4.02%)
(As of 09/29/2023 ET)
Compare
Today's Range
$6.07
$6.60
50-Day Range
$6.06
$7.97
52-Week Range
$3.00
$8.65
Volume
44,782 shs
Average Volume
71,444 shs
Market Capitalization
$630.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50

Centessa Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
31.4% Upside
$8.50 Price Target
Short Interest
Bearish
2.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.85mentions of Centessa Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$235,774 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.74) to ($1.76) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.05 out of 5 stars

Medical Sector

654th out of 972 stocks

Pharmaceutical Preparations Industry

312th out of 455 stocks


CNTA stock logo

About Centessa Pharmaceuticals (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.

CNTA Price History

CNTA Stock News Headlines

[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Where Centessa Pharmaceuticals Stands With Analysts
See More Headlines
Receive CNTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Centessa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNTA Company Calendar

Last Earnings
8/14/2023
Today
10/01/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CNTA
Fax
N/A
Employees
64
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.50
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+31.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-216,210,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.55 per share

Miscellaneous

Free Float
86,163,000
Market Cap
$630.18 million
Optionable
Not Optionable
Beta
1.27
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Saurabh Saha M.D. (Age 46)
    Ph.D., CEO & Director
    Comp: $957.67k
  • Dr. Gregory M. Weinhoff M.B.A. (Age 52)
    M.D., MBA, Principal Accounting Officer & CFO
    Comp: $655k
  • Dr. David M. Chao Ph.D. (Age 55)
    Chief Admin. Officer
    Comp: $655k
  • Ms. Tia L. Bush (Age 52)
    Chief Technology & Quality Officer
  • Ms. Kristen K. Sheppard Esq.
    J.D., Sr. VP of Investor Relations & Corp. Communications
  • Mr. Iqbal J. Hussain L.L.B. (Age 42)
    Gen. Counsel, Chief Compliance Officer & Corp. Sec.
  • Ms. Karen M. Anderson (Age 55)
    Chief People Officer
  • Dr. Antoine Yver M.D. (Age 65)
    M.Sc., MSc, Exec. VP & Chairman of Devel.
  • Dr. David John Grainger Ph.D. (Age 54)
    Chief Innovation Officer
  • Dr. Harris L. Rotman Ph.D.
    Sr. VP of Regulatory Affairs













CNTA Stock - Frequently Asked Questions

Should I buy or sell Centessa Pharmaceuticals stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Centessa Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CNTA shares.
View CNTA analyst ratings
or view top-rated stocks.

What is Centessa Pharmaceuticals' stock price forecast for 2023?

7 brokerages have issued 12-month price objectives for Centessa Pharmaceuticals' shares. Their CNTA share price forecasts range from $4.00 to $15.00. On average, they predict the company's stock price to reach $8.50 in the next twelve months. This suggests a possible upside of 31.4% from the stock's current price.
View analysts price targets for CNTA
or view top-rated stocks among Wall Street analysts.

How have CNTA shares performed in 2023?

Centessa Pharmaceuticals' stock was trading at $3.10 at the beginning of the year. Since then, CNTA shares have increased by 108.7% and is now trading at $6.47.
View the best growth stocks for 2023 here
.

When is Centessa Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our CNTA earnings forecast
.

How were Centessa Pharmaceuticals' earnings last quarter?

Centessa Pharmaceuticals plc (NASDAQ:CNTA) released its earnings results on Monday, August, 14th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.17.

When did Centessa Pharmaceuticals IPO?

(CNTA) raised $285 million in an initial public offering (IPO) on Friday, May 28th 2021. The company issued 15,000,000 shares at $18.00-$20.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Jefferies and Evercore ISI were co-managers.

What is Centessa Pharmaceuticals' stock symbol?

Centessa Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNTA."

How do I buy shares of Centessa Pharmaceuticals?

Shares of CNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Centessa Pharmaceuticals' stock price today?

One share of CNTA stock can currently be purchased for approximately $6.47.

How much money does Centessa Pharmaceuticals make?

Centessa Pharmaceuticals (NASDAQ:CNTA) has a market capitalization of $630.18 million. The company earns $-216,210,000.00 in net income (profit) each year or ($1.81) on an earnings per share basis.

How can I contact Centessa Pharmaceuticals?

Centessa Pharmaceuticals' mailing address is THE DOROTHY HODGKIN BUILDING BABRAHAM RESEARCH CAMPUS, BABRAHAM CAMBRIDGE X0, CB22 3FH. The official website for the company is www.centessa.com. The company can be reached via phone at 44-73-9178-9784 or via email at investorrelations@centessa.com.

This page (NASDAQ:CNTA) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -